FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308374297> ?p ?o ?g. }

• W4308374297 endingPage "e841" @default.
• W4308374297 startingPage "e831" @default.
• W4308374297 abstract "<h2>Summary</h2><h3>Background</h3> The selection and categorisation of laboratory tests in disease activity measures used within systemic lupus erythematosus (SLE) trial endpoints lack strong evidence. We aimed to determine whether longitudinal improvements in routinely measured laboratory tests are associated with measures of clinical improvement in patients with baseline active SLE. <h3>Methods</h3> We included patients from a multicentre longitudinal cohort (recruited between May 1, 2013, and Dec 31, 2019) with active SLE (SLEDAI-2K ≥6) coinciding with an abnormality in at least one of 13 routine laboratory tests, at a visit designated as baseline. At 12 months, we analysed associations between thresholds of improvement in individual laboratory test results, measured as continuous variables, and five clinical outcomes using logistic regression. Primary outcomes were damage accrual and lupus low disease activity state (LLDAS), and secondary outcomes were modified SLE responder index (mSRI), physician global assessment (PGA) improvement of at least 0·3, and flare. <h3>Findings</h3> We included 1525 patients (1415 [93%] women and 110 [7%] men, 1328 [87%] Asian ethnicity) in separate subsets for each laboratory test. The strongest associations with LLDAS and damage protection were seen with improvements in proteinuria (complete response: adjusted odds ratio [OR] 62·48, 95% CI 18·79–208·31 for LLDAS, OR 0·22, 95% CI 0·10–0·49 for damage accrual), albumin (complete response: adjusted OR 6·46, 95% CI 2·20–18·98 for LLDAS, OR 0·42, 95% CI 0·20–1·22 for damage accrual), haemoglobin (complete response: adjusted OR 1·97, 95% CI 1·09–3·53 for LLDAS, OR 0·33, 95% CI 0·15–0·71 for damage accrual), erythrocyte sedimentation rate (complete response: adjusted OR 1·71, 95% CI 1·10–2·67 for LLDAS, OR 0·53, 95% CI 0·30–0·94 for damage accrual), and platelets (complete response: adjusted OR 4·82, 95% CI 1·54–15·07 for LLDAS, OR 0·49, 95% CI 0·20–1·19 for damage accrual). Improvement in serological tests were mainly associated with PGA and mSRI. White cell and lymphocyte count improvements were least predictive. <h3>Interpretation</h3> Improvements in several routine laboratory tests correspond with clinical outcomes in SLE over 12 months. Tests with the strongest associations were discrepant with laboratory tests included in current trial endpoints, and associations were observed across a range of improvement thresholds including incomplete resolution. These findings suggest the need to revise the use of laboratory test results in SLE trial endpoints. <h3>Funding</h3> Abbvie." @default.
• W4308374297 created "2022-11-11" @default.
• W4308374297 creator A5002302692 @default.
• W4308374297 creator A5004488408 @default.
• W4308374297 creator A5009908322 @default.
• W4308374297 creator A5010908061 @default.
• W4308374297 creator A5013050286 @default.
• W4308374297 creator A5014281693 @default.
• W4308374297 creator A5015953107 @default.
• W4308374297 creator A5018166258 @default.
• W4308374297 creator A5019159322 @default.
• W4308374297 creator A5021208900 @default.
• W4308374297 creator A5023220117 @default.
• W4308374297 creator A5029356053 @default.
• W4308374297 creator A5039342892 @default.
• W4308374297 creator A5041077330 @default.
• W4308374297 creator A5041113458 @default.
• W4308374297 creator A5043055068 @default.
• W4308374297 creator A5046294898 @default.
• W4308374297 creator A5047916551 @default.
• W4308374297 creator A5050765170 @default.
• W4308374297 creator A5051595479 @default.
• W4308374297 creator A5055636853 @default.
• W4308374297 creator A5056529867 @default.
• W4308374297 creator A5056597116 @default.
• W4308374297 creator A5060788268 @default.
• W4308374297 creator A5062119183 @default.
• W4308374297 creator A5063503339 @default.
• W4308374297 creator A5064779943 @default.
• W4308374297 creator A5069259297 @default.
• W4308374297 creator A5075742607 @default.
• W4308374297 creator A5079096658 @default.
• W4308374297 creator A5082868970 @default.
• W4308374297 creator A5083314956 @default.
• W4308374297 creator A5088550144 @default.
• W4308374297 creator A5090269416 @default.
• W4308374297 date "2022-12-01" @default.
• W4308374297 modified "2023-10-18" @default.
• W4308374297 title "Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study" @default.
• W4308374297 cites W1977588665 @default.
• W4308374297 cites W2030104307 @default.
• W4308374297 cites W2070527591 @default.
• W4308374297 cites W2091468965 @default.
• W4308374297 cites W2096286605 @default.
• W4308374297 cites W2105253459 @default.
• W4308374297 cites W2108905161 @default.
• W4308374297 cites W2111416025 @default.
• W4308374297 cites W2159106700 @default.
• W4308374297 cites W2159860161 @default.
• W4308374297 cites W2168146874 @default.
• W4308374297 cites W2175492537 @default.
• W4308374297 cites W2199189793 @default.
• W4308374297 cites W2415123980 @default.
• W4308374297 cites W2766331956 @default.
• W4308374297 cites W2790857436 @default.
• W4308374297 cites W2890692328 @default.
• W4308374297 cites W2899569023 @default.
• W4308374297 cites W2925135702 @default.
• W4308374297 cites W2971494308 @default.
• W4308374297 cites W2983004004 @default.
• W4308374297 cites W2995521654 @default.
• W4308374297 cites W3027280317 @default.
• W4308374297 cites W3032908970 @default.
• W4308374297 cites W3085025551 @default.
• W4308374297 cites W3159830316 @default.
• W4308374297 cites W3165895944 @default.
• W4308374297 cites W3205547153 @default.
• W4308374297 cites W4200554903 @default.
• W4308374297 cites W4296447900 @default.
• W4308374297 cites W4307155397 @default.
• W4308374297 doi "https://doi.org/10.1016/s2665-9913(22)00307-1" @default.
• W4308374297 hasPublicationYear "2022" @default.
• W4308374297 type Work @default.
• W4308374297 citedByCount "2" @default.
• W4308374297 countsByYear W43083742972022 @default.
• W4308374297 countsByYear W43083742972023 @default.
• W4308374297 crossrefType "journal-article" @default.
• W4308374297 hasAuthorship W4308374297A5002302692 @default.
• W4308374297 hasAuthorship W4308374297A5004488408 @default.
• W4308374297 hasAuthorship W4308374297A5009908322 @default.
• W4308374297 hasAuthorship W4308374297A5010908061 @default.
• W4308374297 hasAuthorship W4308374297A5013050286 @default.
• W4308374297 hasAuthorship W4308374297A5014281693 @default.
• W4308374297 hasAuthorship W4308374297A5015953107 @default.
• W4308374297 hasAuthorship W4308374297A5018166258 @default.
• W4308374297 hasAuthorship W4308374297A5019159322 @default.
• W4308374297 hasAuthorship W4308374297A5021208900 @default.
• W4308374297 hasAuthorship W4308374297A5023220117 @default.
• W4308374297 hasAuthorship W4308374297A5029356053 @default.
• W4308374297 hasAuthorship W4308374297A5039342892 @default.
• W4308374297 hasAuthorship W4308374297A5041077330 @default.
• W4308374297 hasAuthorship W4308374297A5041113458 @default.
• W4308374297 hasAuthorship W4308374297A5043055068 @default.
• W4308374297 hasAuthorship W4308374297A5046294898 @default.
• W4308374297 hasAuthorship W4308374297A5047916551 @default.
• W4308374297 hasAuthorship W4308374297A5050765170 @default.
• W4308374297 hasAuthorship W4308374297A5051595479 @default.
• W4308374297 hasAuthorship W4308374297A5055636853 @default.

• next